Author: Sreelatha M

Categories
Corporate

₹148 Lakh crore wealth boom for India’s top firms

India’s top listed companies have created record wealth over the past five years. The latest Motilal Oswal Wealth Creation Study reports that the top 100 companies added ₹148 lakh crore in market value between March 2020 and March 2025. This is the highest increase seen since the study began 30 years ago.

The sharp rise in wealth came during a period of strong corporate earnings and steady market participation. Domestic investors also played a major role in keeping markets stable and active.

Bharti Airtel emerged as the biggest wealth creator in this five-year cycle. The telecom major added nearly ₹8 lakh crore to its market value. Strong subscriber growth and higher data usage supported its performance. ICICI Bank and State Bank of India followed Airtel, driven by healthier balance sheets and better credit growth.

The study highlights that the financial sector continues to contribute the most to overall wealth creation. Banks and non-banking financial companies saw strong demand, improved asset quality and better profitability.

A separate list in the study tracks the fastest wealth creators. BSE Ltd, the stock exchange operator, topped this category due to a high compound annual growth rate. The company benefited from increased trading activity and rising investor participation.

Defence and capital goods companies also stood out. Hindustan Aeronautics Ltd (HAL) delivered consistent performance each year. It was ranked the most consistent wealth creator and the best overall performer. Other defence players such as Bharat Dynamics and Bharat Electronics also saw strong gains. Higher government spending on defence supported this trend.

The study notes the rising importance of public sector undertakings. Several PSUs in energy, defence and utilities reported sharp increases in market value. Investor interest in these companies grew as they reported stronger profits and benefited from policy support.

Motilal Oswal says the last five years represent a broad and healthy phase for India’s equity markets. It adds that India may be entering a long multi-year growth cycle. The firm believes that rising incomes, higher savings and economic expansion will continue to support wealth creation.

The study concludes that India’s markets are well-positioned for further gains if earnings growth remains steady and investor participation continues.

Also Read: ICICI Prudential AMC ₹10,602 cr IPO opens

Categories
Corporate

Park Medi World IPO ₹920 cr, nearly fully subscribed

Park Medi World’s initial public offering (IPO), targeting around ₹920 crore, is in its third and final day. Priced between ₹154 and ₹162 per share, the IPO includes a mix of new shares and shares sold by existing investors.

In the grey market, where unofficial trades hint at potential listing gains, the premium has eased to around ₹8–₹9 per share, roughly 5% above the issue price. This marks a softening from earlier levels, signaling a slight cooling of short-term trading excitement.

By the end of Day 2, the IPO was almost fully subscribed. Retail investors applied for 1.19 times their allocation, while non-institutional investors applied for 1.38 times. Institutional investors were more cautious, covering only 32% of their quota.

The company plans to use the proceeds to repay debt, expand its hospital network, purchase medical equipment, and fund growth initiatives. Park Medi World operates 14 multi-speciality hospitals in North India, with over 3,000 beds and more than 30 medical specialties, making it a significant player in the region’s healthcare sector.

Financially, the company has reported steady growth in revenue and profits over the past few years. Its expansion strategy, through acquisitions and new hospital projects, has helped strengthen its position in the competitive healthcare market.

Analysts see the IPO as attractive for long-term investors, highlighting the company’s strong fundamentals and the rising demand for quality healthcare services across India.

The IPO closes on 12 December 2025, with listing expected later this month. Investors are watching both subscription trends and grey market movements closely, as they offer a glimpse into potential listing performance.

Park Medi World’s offering reflects continued investor interest in the healthcare sector, combining growth potential with an established hospital network and a wide range of specialized services.

Also Read: IndiGo offers Rs 10,000 vouchers to passengers

Categories
Corporate

ICICI Prudential AMC ₹10,602 cr IPO opens

The ICICI Prudential Asset Management Company (AMC) IPO opened on December 12, 2025. Investors are watching it closely. This is one of India’s biggest fundraisings this year.

The IPO is an offer for sale (OFS). Promoters are selling their shares. No fresh equity is being issued. The issue aims to raise around ₹10,602 crore. The price band is ₹2,061–₹2,165 per share, giving the AMC a valuation of about ₹1.07 lakh crore.

The subscription window will close on December 16. Shares are expected to list on December 19. On the first day, subscription was moderate. Retail and non‑institutional investors led the early bids. Institutional participation is expected to pick up in the coming days.

In the grey market, unlisted shares are trading at a premium of ₹150–₹177. This signals a potential listing gain of 7–8 percent. Grey market trends often hint at market sentiment. The current premium shows optimism for the IPO.

Before the public offer, the AMC raised more than ₹3,000 crore from anchor investors. Top domestic and international institutions took part. Analysts say this shows strong confidence and adds credibility to the IPO.

ICICI Prudential AMC is a joint venture between ICICI Bank (51%) and Prudential Corporation Holdings (49%). It is one of India’s largest asset managers. The company manages equity, debt, and hybrid funds. It serves both retail and institutional clients.

Experts say the IPO may attract medium- to long-term investors. Positive grey market signals and strong anchor support are encouraging. This IPO is the fifth ICICI Group company to list. It highlights growing investor appetite for established financial companies in India in 2025.

Also Read: Park Medi World IPO ₹920 cr, nearly fully subscribed

Categories
Beyond

Gold falls ₹140, Silver near ₹2 lakh on Dec. 12

Gold prices in India dropped a little on 12 December 2025. The price of 24-carat gold was about ₹132,340 for 10 grams, down roughly ₹140 from the previous day. 22-carat gold also fell by around ₹128. The same trend was seen across major cities including Delhi, Mumbai, Bengaluru, Hyderabad and Chennai. Prices in India remained higher than Dubai because of import duty and local taxes.

The small fall in gold rates came after soft global cues, a weaker US dollar and expectations of future interest rate cuts in the US. These international factors continue to influence gold prices in the domestic market.

Silver prices, however, held steady at stronger levels. Silver was priced at around ₹201 per gram, which is close to ₹2,01,000 per kilogram in many parts of India. Some cities reported slightly higher rates depending on local demand.

Both gold and silver prices may vary from shop to shop due to making charges, GST and regional differences.

Also Read: Sensex jumps 300 Points, Nifty moves above 25,950

Categories
Corporate

Corona Remedies IPO allotment finalised, listing on Dec.15

The allotment for the Corona Remedies Ltd. IPO was finalised on 11 December 2025, marking an important step for investors who applied to the ₹655-crore issue. The IPO, which opened from 8 to 10 December, received an exceptionally strong response across all investor categories, making it one of the most subscribed issues of the year.

Investors can now check whether they have been allotted shares. The allotment status is available on the website of Bigshare Services, the official registrar for the IPO. Applicants can log in using their PAN number, application number, or DP ID. The allotment details can also be checked on the BSE and NSE portals. Those who have received shares will see them credited to their demat accounts by 12 December, while refunds for non-allottees will also be processed on the same day.

The Corona Remedies IPO received a huge market response, with the issue subscribed over 130 to 137 times. This means demand was far greater than the shares available, indicating strong interest from investors ranging from retail buyers to qualified institutional investors (QIIs) and high-net-worth individuals. The high subscription levels show the confidence investors have in the company’s business, growth record, and presence in the pharmaceutical sector.

Grey market activity has also remained strong. The IPO is trading at a premium of around 27–28%, signaling expectations of a positive listing. A strong grey market premium usually reflects positive sentiment and indicates that investors believe the stock may list above the upper end of the price band, which for this IPO was ₹1,008 to ₹1,062 per share.

Corona Remedies is a growing pharmaceutical company with a diverse portfolio across women’s health, cardio-diabetes, pain management, urology, and nutritional supplements. Its steady revenue growth and nationwide distribution network have added to investor confidence.

The stock is scheduled to list on the BSE and NSE on 15 December 2025, and market watchers will be closely observing its debut price and trading movement. For now, investors are checking the allotment details and preparing for the stock’s listing, which is expected to draw strong interest on opening day.

Also Read: TCS to buy US firm Coastal Cloud for $700 million

Categories
Technology

Instagram introduces “Your Algorithm”

Instagram has rolled out a new AI-powered feature, “Your Algorithm,” designed to give users greater control over the content they encounter in their Reels feed. The tool provides a clear view of the topics Instagram believes interest a user, allowing them to add new topics, remove ones they no longer follow, or adjust how prominently each appears.

The feature is accessible through the Reels tab, where users can tap the icon in the top-right corner to see a personalised summary of their interests. From there, they can update their preferences, ensuring that the Reels feed reflects their evolving tastes. Some users can even share their interest list via Instagram Stories, offering a glimpse into the topics shaping their feed.

Meta, Instagram’s parent company, says the move aligns with its broader goal of enhancing transparency and user empowerment in algorithm-driven platforms. By giving users insight into why they see certain content and the ability to influence it, Instagram aims to foster a more engaging and relevant experience.

Currently available in the United States, the company plans to roll out the feature globally in English in the coming months. Over time, similar controls will be introduced across other areas of the app, including the Explore tab, extending user influence beyond Reels.

Industry experts suggest that such initiatives are critical in building trust and satisfaction among social media users, as people increasingly seek to shape their digital experiences rather than passively consume algorithm-curated content. Instagram’s approach signals a shift toward a more user-centric model, where AI assists rather than dictates what appears on a feed.

“Your Algorithm” represents a thoughtful blend of artificial intelligence and user agency, giving individuals both insight and control. By humanising the algorithm and putting decision-making power into the hands of users, Instagram is taking a meaningful step toward more transparent, personalised, and enjoyable digital engagement.

Also Read: TCS to buy US firm Coastal Cloud for $700 million

Categories
1 Minute-Read

Aequs shares listed at 13% premium on day 1

Aequs’ shares debuted on the stock market on Dec 10 at ₹396, marking a 13% premium over its IPO price of ₹350.

Despite this positive listing, the stock fell short of grey market expectations, which had predicted a higher premium. The company’s IPO had garnered strong investor interest, being subscribed multiple times.

Aequs, an aerospace and engineering services firm, aims to leverage this listing to strengthen its market presence and fund expansion plans, including scaling operations and exploring new business opportunities.Analysts noted that while the listing was encouraging, it highlighted a gap between market anticipation and actual investor response.

Categories
Corporate

Amazon announces $35 billion India growth plan by 2030

Amazon has announced it will invest over $35 billion in India by 2030. This is in addition to the $40 billion it has already invested in the country. The investment will focus on three areas: artificial intelligence, exports, and job creation.

Since 2010, Amazon has helped digitise more than 12 million small businesses in India. It has supported around $20 billion in exports and created 2.8 million jobs, directly or indirectly.

With the new plan, Amazon expects to generate 1 million more jobs by 2030. These jobs will include technology, logistics, operations, customer support, and other related sectors.

Amazon also aims to increase its e-commerce exports from $20 billion to $80 billion by 2030. The company plans to expand access to AI tools for small businesses. This includes improving online shopping experiences with AI features like visual search and multilingual support. Amazon will also offer AI education and training to students.

The announcement was made at the Amazon Smbhav Summit 2025 in New Delhi. The company shared a report highlighting its impact on India’s digital growth, small business empowerment, and job creation over the last decade.

Amazon’s new investment shows its confidence in India’s growing digital economy. It also aligns with national goals to boost AI, strengthen infrastructure, and support small businesses.

This step reinforces Amazon’s commitment to helping India’s economy grow while creating opportunities for millions of people.

Also Read: Anupam Rasayan buys US firm Jayhawk for $150 million

Categories
1 Minute-Read

Corona Remedies IPO

The Corona Remedies IPO, priced between ₹1,008–₹1,062 per share, saw robust demand, closing Day 3 with a 32× overall subscription.

The Non-Institutional Investor (NII) segment led the frenzy, oversubscribed 107×, while retail and qualified institutional buyers also showed strong interest.

Grey Market Premium (GMP) surged to around ₹30 per share, indicating high listing expectations. The IPO, valued at ₹655 crore through an offer-for-sale, reflects strong market confidence.

Investors are keenly watching the listing, but experts advise caution given the steep oversubscription and potential volatility post-listing.

Categories
Corporate

Anupam Rasayan buys US firm Jayhawk for $150 million

In a major overseas expansion, Anupam Rasayan India has agreed to acquire US-based Jayhawk Fine Chemicals for about $150 million, marking one of its biggest international moves so far.

The deal includes the purchase of all Jayhawk’s equity and the settlement of outstanding loans. After adjusting for Jayhawk’s cash balance, the enterprise value of the transaction works out to around $134 million.

The acquisition gives Anupam Rasayan its first manufacturing footprint in the United States. This is expected to bring the company closer to global customers and strengthen its position in high-margin, niche chemical segments.

Jayhawk Fine Chemicals is known for its expertise in high-purity and complex chemistries. Its capabilities include advanced chemical processes used in sectors such as aviation, electronics, semiconductors and other industrial applications. The company reported revenue of nearly $78 million in 2024, with an EBITDA of around $15 million.

According to Anupam Rasayan’s management, the deal is aimed at creating strong operational and strategic synergies. The plan is to combine Jayhawk’s technology and customer relationships in the US with Anupam’s cost-efficient manufacturing base in India. This “dual manufacturing” model is expected to improve supply reliability for global clients while keeping costs competitive.

The transaction will be funded through a mix of internal funds, debt and a large quasi-equity investment from a global fund. Importantly, the company has clarified that this investment will not dilute Anupam’s management control.

After the acquisition, Anupam Rasayan expects its business mix to change significantly. The share of “performance materials” in its revenue is likely to rise to about 35%, compared to roughly 12% earlier. Agrochemicals are expected to continue as a key segment, contributing around 40–45% of revenues.

Market analysts have largely viewed the acquisition as a strategic, long-term positive, saying the deal strengthens Anupam’s global presence and opens new growth avenues in high-value industries.

With this move, Anupam Rasayan is positioning itself as a more diversified and globally integrated specialty-chemicals company, reducing dependence on any single geography.

Also Read: BlackRock arm invests $225 million in Aditya Birla Renewables